Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure

BACKGROUND: There are limited bladder-preserving therapeutic options for patients with high-risk non-muscle invasive bladder cancer (NMIBC) after failed Bacillus Calmette-Guérin (BCG) therapy. Salvage intravesical docetaxel therapy was described in 2006 but has not been validated outside of the orig...

Descripción completa

Detalles Bibliográficos
Autores principales: Shantharam, Govind, Amin, Ali, Pereira, Jorge, Kott, Ohad, Mueller-Leonhard, Catrina, Mega, Anthony, Golijanin, Dragan, Gershman, Boris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137085/
https://www.ncbi.nlm.nih.gov/pubmed/34084119
http://dx.doi.org/10.1097/CU9.0000000000000010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137085/
https://www.ncbi.nlm.nih.gov/pubmed/34084119
http://dx.doi.org/10.1097/CU9.0000000000000010

Ejemplares similares